Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir and Ritonavir Effect on Methadone PK in Healthy Volunteers
NCT02245451Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2005
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir and ritonavir in human immunodeficiency virus infection (HIV) and opioid use disorder (OUD), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve for 0 to 24 hours of methadone, Maximum concentration of methadone at 24 hours and 3 more. Started Jan 2005; status: completed.
02
Drugs
tipranavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02245451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245451.